Utilized for type 2 diabetes mellitus to manage blood glucose levels and support insulin response.
Mechanism of Action
Sitagliptin inhibits the DPP-4 enzyme, which increases the levels of incretin hormones. These hormones stimulate insulin secretion and decrease glucagon production in a glucose-dependent manner, effectively lowering blood sugar levels.
Route of Administration
Oral
Onset Time
1–2 weeks
Duration
24 hours
Contraindications
Hypersensitivity to sitagliptin, Severe renal impairment (requires dose adjustment)
Severe Adverse Events
Pancreatitis, Severe hypersensitivity, Renal failure — requires immediate medical attention
Information related to Sitagliptin is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
